PT2547205T - Novos métodos para atingir células estaminais cancerígenas - Google Patents

Novos métodos para atingir células estaminais cancerígenas

Info

Publication number
PT2547205T
PT2547205T PT117571356T PT11757135T PT2547205T PT 2547205 T PT2547205 T PT 2547205T PT 117571356 T PT117571356 T PT 117571356T PT 11757135 T PT11757135 T PT 11757135T PT 2547205 T PT2547205 T PT 2547205T
Authority
PT
Portugal
Prior art keywords
stem cells
cancer stem
novel methods
targeting cancer
targeting
Prior art date
Application number
PT117571356T
Other languages
English (en)
Portuguese (pt)
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Publication of PT2547205T publication Critical patent/PT2547205T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
PT117571356T 2010-03-19 2011-03-21 Novos métodos para atingir células estaminais cancerígenas PT2547205T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19

Publications (1)

Publication Number Publication Date
PT2547205T true PT2547205T (pt) 2024-05-27

Family

ID=50940329

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117571356T PT2547205T (pt) 2010-03-19 2011-03-21 Novos métodos para atingir células estaminais cancerígenas

Country Status (11)

Country Link
EP (2) EP3108750B1 (OSRAM)
JP (11) JP2014098049A (OSRAM)
CN (3) CN107311969B (OSRAM)
CA (3) CA2993363A1 (OSRAM)
DK (1) DK3108750T3 (OSRAM)
ES (1) ES2689928T3 (OSRAM)
HU (1) HUE066482T2 (OSRAM)
NZ (2) NZ712826A (OSRAM)
PT (1) PT2547205T (OSRAM)
RU (2) RU2015142279A (OSRAM)
SG (3) SG10201704745UA (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027443T2 (en) 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
SG10201704745UA (en) * 2010-03-19 2017-07-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
CN103025159A (zh) * 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル, インコーポレイテッド がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン
EA201792623A1 (ru) * 2015-06-03 2018-04-30 Бостон Биомедикал, Инк. Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP6751658B2 (ja) 2016-11-15 2020-09-09 クラリオン株式会社 音声認識装置、音声認識システム
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
EP1146869A2 (en) * 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US20060142271A1 (en) * 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
AR058676A1 (es) * 2005-09-30 2008-02-20 Smithkline Beecham Corp Composicion farmaceutica que contiene (s) -(-)-n-( alfa- etilbencil) -3- hidroxi- 2- fenilquinolina-4-carboxamida ( talnetant), povidona , manitol y tensioactivo, procedimiento para prepararla y forma de dosificacion que la comprende
EP1860126A1 (en) * 2006-05-26 2007-11-28 INEOS Manufacturing Belgium NV Polyolefin powder
HUE027443T2 (en) * 2007-09-10 2016-10-28 Boston Biomedical Inc A novel class of Stat3 pathway inhibitors and tumor stem cell inhibitors
JP5719770B2 (ja) * 2008-07-08 2015-05-20 ベータ・ファーマ・インコーポレイテッドBeta Pharma, Inc. 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途
SG10201704745UA (en) * 2010-03-19 2017-07-28 Boston Biomedical Inc Novel compounds and compositions for targeting cancer stem cells
CN103002890A (zh) * 2010-03-19 2013-03-27 波士顿生物医学公司 靶向癌症干细胞的新的化合物和组合物
CN103025159A (zh) * 2010-03-19 2013-04-03 波士顿生物医学公司 靶向癌症干细胞的新方法

Also Published As

Publication number Publication date
CN107311969A (zh) 2017-11-03
JP2020114888A (ja) 2020-07-30
EP3295796A1 (en) 2018-03-21
NZ712826A (en) 2017-03-31
CN107311969B (zh) 2022-01-28
JP6246169B2 (ja) 2017-12-13
JP2020063308A (ja) 2020-04-23
CA2959931A1 (en) 2011-09-22
CA2993363A1 (en) 2011-09-22
NZ701237A (en) 2016-04-29
JP2022020002A (ja) 2022-01-27
JP2018115209A (ja) 2018-07-26
EP3108750A1 (en) 2016-12-28
HUE066482T2 (hu) 2024-08-28
JP2018002744A (ja) 2018-01-11
SG10201704745UA (en) 2017-07-28
CN104016951B (zh) 2016-07-13
JP2014098048A (ja) 2014-05-29
DK3108750T3 (en) 2018-10-22
JP2015232037A (ja) 2015-12-24
JP2014098049A (ja) 2014-05-29
JP2015098489A (ja) 2015-05-28
CN106860443A (zh) 2017-06-20
EP3108750B1 (en) 2018-07-04
ES2689928T3 (es) 2018-11-16
SG10201706265PA (en) 2017-08-30
RU2657750C1 (ru) 2018-06-15
JP2014098050A (ja) 2014-05-29
JP5993390B2 (ja) 2016-09-14
SG10201502079VA (en) 2015-06-29
JP2016222723A (ja) 2016-12-28
CA2959951A1 (en) 2011-09-22
CN104016951A (zh) 2014-09-03
RU2015142279A3 (OSRAM) 2019-02-26
RU2015142279A (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
PL2547205T3 (pl) Nowe sposoby do celowania nowotworowych komórek macierzystych
IL220756A0 (en) Herbicide-tolerant plants
IL225635A (en) Device for cell culture with internal tools
PT2785834T (pt) Composição de células estaminais melhorada
HUE066482T2 (hu) Új eljárások rákõssejtek megcélzására
EP2601290A4 (en) SOMATIC STEM CELLS
EP2772268B8 (en) Cancer stem cell-specific molecule
GB201016139D0 (en) Cancer phosholipidome
IL255309B (en) Reprogramming of cancer cells
PL2547766T3 (pl) Rośliny tolerancyjne względem herbicydów
EP2760996A4 (en) SOMATIC STEM CELLS
GB201012590D0 (en) Methods for diagnosing cancer
WO2011116344A9 (en) Targeting cancer stem cells
EP2533789A4 (en) METHOD FOR IMPROVING THE FUNCTIONALITY OF SPERM
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
PL3536334T3 (pl) Szczepionki przeciw rakowi ukierunkowane na komórki macierzyste raka
PL2568796T3 (pl) Półzawieszany pług obracalny
WO2012106368A9 (en) Methods for inhibiting prostate cancer
SG196714A1 (en) Cancer stem cell inhibition
GB201021372D0 (en) CD24 cancer stem cell
ZA201205860B (en) Herbicide-tolerant plants
AU2011900981A0 (en) Inhibition of cancer stem cells
GB201012495D0 (en) Targeted differntiation of stem cells
PL2593113T3 (pl) Terapia komórkowa
GB201019304D0 (en) Cells